January 28, 2019

PRODUCT MONOGRAPH. PR. Cathflo. ® alteplase, recombinant . cell line into which the cDNA for alteplase has been genetically inserted. Read all of this leaflet carefully before you What Actilyse Cathflo is and what it is used for. 2. Contents of the pack and other information. 1. Drug monographs for CATHFLO ACTIVASE provide an overview of the drug Keeping the vial of Sterile Water for Injection upright, insert the piercing pin of the .

Author: Voshicage Zukus
Country: Guatemala
Language: English (Spanish)
Genre: Technology
Published (Last): 27 April 2004
Pages: 297
PDF File Size: 7.49 Mb
ePub File Size: 5.61 Mb
ISBN: 470-2-64390-975-4
Downloads: 82612
Price: Free* [*Free Regsitration Required]
Uploader: Dami

Skip auxiliary navigation Press Enter. Pre-treatment with oral anticoagulants is reported to be an independent risk factor for intracranial hemorrhage in thrombolytic-treated patients. The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc.

Monitor patients treated with Cathflo Activase for signs of hypersensitivity and treat appropriately if necessary. There is an increased risk of intracranial hemorrhage in patients with severe neurological deficit e. The risks of alteplase therapy may be increased in patients with significant hepatic impairment and should be weighed against the anticipated benefits. Promptly evaluate any signs or symptoms of blood loss in patients on concomitant therapy. Moderate An increased risk of bleeding may occur when thrombolytic agents are used following agents that cause clinically significant thrombocytopenia including antithymocyte globulin.

PDR Search

Rates of serious adverse reactions and catheter function restoration were similar between pediatric patients and those seen in adults. Major Ginkgo biloba should be used cautiously in patients taking thrombolytic agents. In my experience, one hour dwell is what we usually need. Date range on this day between these dates. Because omega-3 fatty acids inhibit platelet aggregation, caution is advised when icosapent ethyl is used concurrently with anticoagulants, platelet inhibitors, or thrombolytic agents.


Administer antihypertensive medications to maintain blood pressure at cathfl below these values. Avoid concurrent use of herbs which interact with thrombolytic agents when possible. Major Patients receiving thrombolytic agents are at increased risk of bleeding during drotrecogin alfa therapy.

Prothrombin times stabilized during administration of both agents will change slightly when heparin is discontinued. I have seen no official recommendation and no study or data, but I have had multiple discussions about this practice as an effective alternative to catheter stripping or replacement due to fibrin sheath that does not respond to 2 hour dwell.

Although clinical practice guidelines recommend expanded use of alteplase at 3 to 4.

All ONS Member Community

In an outpatient unit, I can imagine this greatly affects turn around time and the number of patients you can treat daily, etc. Bleeding events related to drugs that inhibit serotonin reuptake have ranged from ecchymosis to life-threatening hemorrhages. Moderate Platelet aggregation may be impaired by serotonin norepinephrine reuptake inhibitors SNRIs due to platelet serotonin depletion, possibly increasing inserf risk of a bleeding complication e.

Cathflo Activase has not been studied in patients known to be at risk for bleeding packagd that may be associated with the use of thrombolytics.

Single-Use Vial Lytic Thrombolytic – Cathflo® Activase® (alteplase)

Monitor patients treated with Cathflo Activase for signs of hypersensitivity and treat appropriately if necessary.

If catheter function is not restored at minutes after 1 dose caathflo Cathflo, a second dose may be instilled see Instructions for Administration. All fields are required. Atrial fibrillation, mitral stenosis, thrombosis. Keeping the vial of Sterile Water for Injection upright, insert the piercing pin of the transfer device provided by the manufacturer vertically into the center of the stopper.


Related Drug Information Drug Summary. Gently irrigate the catheter with 0. Systemic alteplase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites. FDA-approved dosing with Cathflo 8. Thank you to all who responded to my post and for the helpful information about how other practices During the first hour, inaert mg is administered over one hour, as a 6—10 mg IV bolus administered over 1—2 minutes then the remaining 50—54 mg, given by IV infusion over the remainder of the hour.

Complete dissolution should occur within 3 minutes.

Data czthflo published studies and case reports on alteplase use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. Let me know if you have further questions!

Major During and after therapy, avoid the concomitant use of Yttrium Y ibrutumomab tiuxetan with drugs that interfere with coagulation such as thrombolytic agents; the risk of bleeding may packkage increased. For reestablishing patency of an occluded IV catheter.

We do not treat before we are assured that the line is patent and in the right place. Moderate Inserg bruising or bleeding at the injection site may occur when using hyaluronate sodium with thrombolytic agents, especially if used within the 3 weeks prior to the procedure. Alteplase may increase the risk of thromboembolic events in these conditions where there is a high likelihood of left heart thrombus, such as patients with mitral stenosis or atrial fibrillation.